CENIX
Desconocido
Athero-Flux: Targeting novel lipid pathways for treatment of cardiovascular disease
CENIX BIOSCIENCE GMBH
participó en un
FP7:
Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from ach...
Financiado
Financiado
MULTIMOD: Multi layer network modules to identify markers for personalized medication in complex diseases
CENIX BIOSCIENCE GMBH
participó en un
FP7:
The symptoms of complex disease like allergy, obesity and cancer depend on the products of multiple interacting genes. High-throughput techn...
Financiado
Financiado
MEHTRICS: Micropattern Enhanced High Throughput RNA Interference for Cell Screening
The MEHTRICS proposal aims to challenge the current limits of HT cell-based screening by combining HT-RNAi with an emerging new technology f...
Financiado
Financiado
CARDIOMIR: Development of microRNA Medicines for Cardiac Metabolic Diseases A Targeted European Exchange Progr...
CENIX BIOSCIENCE GMBH
participó en un
FP7:
An urgent need exists for more specific treatment options to target the metabolic changes and the related inflammatory pathways during HF. T...
Financiado
Financiado
TACIT: Targeted Amphoteric Carriers in ImmunoTherapy
CENIX BIOSCIENCE GMBH
participó en un
FP7:
The past year has been exciting for oligonucleotide-based drug discovery and development. The Nobel Prize was awarded to Mello and Fire for...
Financiado
Financiado
* No se disponen de datos de la empresa actual.